Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
about
Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative reviewThe safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyKhat use and neurobehavioral functions: suggestions for future studiesDurability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeysIs ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in othersDisposition of MDMA and metabolites in human sweat following controlled MDMA administrationPharmacological treatment of anxiety disorders: current treatments and future directionsDuloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory studyClinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)A window into the intoxicated mind? Speech as an index of psychoactive drug effectsMDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study.3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity.A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA.Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).A comprehensive review of MDMA and GHB: two common club drugs.Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting.Preventing problems in Ecstasy users: reduce use to reduce harm.Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.Effects of MDMA on sociability and neural response to social threat and social reward.A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers.Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteersTolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.MDMA Impairs Response to Water Intake in Healthy VolunteersPlasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.Geonotoxicity study of illegal drug MDMA and its nitroso derivative N-MDMA by micronucleus and chromosomal aberration tests using Chinese hamsger lung fibroblast cell line.Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination.Secondary psychoses: an update.The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users.Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance.Risk of injury from alcohol, marijuana and other drug use among emergency department patients.Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.
P2860
Q22305514-4019516F-2C9A-496D-B29E-63D0C6F0FCB9Q24606265-71300338-2212-4FC1-BE46-2FA0B4E4A770Q24610235-22A65E53-2EA6-4AB7-8244-8BE3201DC099Q24620135-E4EE016F-4205-4C68-AC12-1AB25862FF36Q24629918-B704BECF-C96C-4A29-81C1-06CE0F535215Q24630561-8E4D1AE1-CE0B-449C-B7E0-8C81A1BB5DE3Q24658430-360EF147-B220-4C42-ADF1-8E2EDE525BE5Q26851461-A28908B7-C141-429D-B4ED-8BEC310C3EA9Q28483370-8EAC7975-6A97-4365-943B-6B3DA61276E3Q28484562-9673F4D2-2AC5-4B6F-A3A3-219B04ACB4FEQ30404060-BDFE1131-AF1E-4E18-B366-86CBDFE0175CQ33390410-38B04B7C-C202-47D0-86C7-D864AFAD5E81Q33923908-0CCF0A0E-AB4C-4280-B365-C13EB7471100Q34190116-0ABAFE46-7B9D-4F4C-897E-6671448844CBQ34359604-23512856-71BC-49AF-80B2-A3C556E4E37FQ34420092-63FD5EA6-ADF5-43C1-9B14-5761335414AAQ34476901-A144A00F-52B2-4134-A834-46A2E96C9BBFQ34675745-BC5EC8A5-688A-4ED2-9434-17554687E547Q35105557-D69498EB-38D5-430D-9367-215D1676E78DQ35175998-6AEE2B3B-DFB1-4692-A8F4-323D6E82C573Q35604001-31CCD60B-9FA2-4B06-A743-4251AB0137F9Q35823012-AE530C96-7307-4FFE-85C2-14146025C9A4Q35895888-4D5A63A8-29BB-4F5A-B951-B44C7AA29BE7Q36410788-0B8B4459-EE0D-462B-955B-8B5DF04CF214Q36502642-F96CF565-6F7E-430D-9250-F9D044371F8DQ36666580-0F31C45B-1B86-4EF5-80C6-64C3B7979082Q36983556-E414E63C-2562-4634-9811-1449E39B146AQ37043838-AE62306C-63ED-4E92-B20B-4A905CA067E0Q37146495-0EA60F4F-F2C4-4E51-A0CA-2C30F85049BEQ37295701-99806069-4469-4E2A-B8DE-9934282731B8Q37871581-72064460-21A5-47B0-8A01-7992A1ED7979Q38087564-46D11FE3-E39B-41A5-8229-717E9CFBFD8AQ38376332-5CAF8F31-2AF3-4AFA-A311-5FD66ABFD9BBQ38392772-7AD3B228-B88A-44CD-8FEF-B3D99F880EAEQ38423853-AE6117A1-4D8A-4A6F-B64C-AA8B670E336BQ38742100-58D72BC5-9F61-4622-B2EA-137ABF9C9E66Q39548034-60C038A6-4D8E-4EF2-B816-1A068C55413EQ40007746-58BB8A35-9C26-4325-A7F6-6F912A1A4557Q40028400-C6797CC4-2094-4B5A-A103-994E88146B6CQ40359394-66BEC006-5E23-4C27-A5F6-4DFBEA0553FC
P2860
Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@ast
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@en
type
label
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@ast
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@en
prefLabel
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@ast
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@en
P2093
P1476
Human pharmacology of 3,4-meth ...... rmance and subjective effects.
@en
P2093
Poudevida S
de la Torre R
P304
P356
10.1097/00004714-200008000-00010
P407
P577
2000-08-01T00:00:00Z